Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report

Myasthenia gravis with anti-muscle-specific tyrosine kinase antibodies during therapy for multiple myeloma: a case report

Abstract Background The onset of myasthenia (MG) gravis with anti-muscle-specific tyrosine kinase (MuSK) antibodies most commonly peaks in the fourth decade of life, and MG with MuSK antibodies (MuSK-MG) rarely coexists with a malignant tumor. To date, MuSK-MG has not been reported in multiple myelo...

Full description

Bibliographic Details
Main Authors: Shoko Sakano, Hirofumi Matsuyama, Hidehiro Ishikawa, Akihiro Shindo, Yuichiro Ii, Keita Matsuura, Minoru Mizutani, Norikazu Kawada, Hidekazu Tomimoto
Format: Article
Language:English
Published: BMC 2020-06-01
Series:BMC Neurology
Subjects:
Myasthenia gravis
Anti-muscle-specific tyrosine kinase antibodies
Multiple myeloma
Bortezomib
Case report
Online Access:http://link.springer.com/article/10.1186/s12883-020-01813-1

Internet

http://link.springer.com/article/10.1186/s12883-020-01813-1

Similar Items